Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yun-Long Li

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery|November 19, 2009
[Analysis of clinical characteristics of gastrointestinal cancer in Heilongjiang province, China 1998 to 2007]Xiao-ming Zou, Xi-shan Wang, Yun-long Li, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2007
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosisWenqing Yao, Jincong Zhuo, David M Burns, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2008
Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moietiesJames R Corte, Tianan Fang, Donald J P Pinto, et al.
Plos One|June 22, 2018
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignanciesHolly Koblish, Yun-Long Li, Niu Shin, et al.
Bioorganic & Medicinal Chemistry Letters|May 10, 2022
Discovery of 1'-(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3'-pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11β-HSD1 using a scaffold-hopping approachColin Zhang, Meizhong Xu, Chunhong He, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 12, 2017
INCB040093 Is a Novel PI3K<i>δ</i> Inhibitor for the Treatment of B Cell Lymphoid MalignanciesNiu Shin, Yun-Long Li, Song Mei, et al.
Journal of Medicinal Chemistry|May 27, 2026
Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune DiseasesJincong Zhuo, Yun-Long Li, Ding-Quan Qian, et al.
ACS Medicinal Chemistry Letters|November 22, 2019
INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)Eddy W Yue, Yun-Long Li, Brent Douty, et al.
Cancer Biology & Therapy|April 22, 2006
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cellsPhillip C C Liu, Xiangdong Liu, Yanlong Li, et al.
Journal of Medicinal Chemistry|January 30, 2007
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancerWenqing Yao, Jincong Zhuo, David M Burns, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery|November 19, 2009
[Analysis of clinical characteristics of gastrointestinal cancer in Heilongjiang province, China 1998 to 2007]Xiao-ming Zou, Xi-shan Wang, Yun-long Li, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2007
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosisWenqing Yao, Jincong Zhuo, David M Burns, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2008
Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moietiesJames R Corte, Tianan Fang, Donald J P Pinto, et al.
Plos One|June 22, 2018
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignanciesHolly Koblish, Yun-Long Li, Niu Shin, et al.
Bioorganic & Medicinal Chemistry Letters|May 10, 2022
Discovery of 1'-(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3'-pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11β-HSD1 using a scaffold-hopping approachColin Zhang, Meizhong Xu, Chunhong He, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 12, 2017
INCB040093 Is a Novel PI3K<i>δ</i> Inhibitor for the Treatment of B Cell Lymphoid MalignanciesNiu Shin, Yun-Long Li, Song Mei, et al.
Journal of Medicinal Chemistry|May 27, 2026
Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune DiseasesJincong Zhuo, Yun-Long Li, Ding-Quan Qian, et al.
ACS Medicinal Chemistry Letters|November 22, 2019
INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)Eddy W Yue, Yun-Long Li, Brent Douty, et al.
Cancer Biology & Therapy|April 22, 2006
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cellsPhillip C C Liu, Xiangdong Liu, Yanlong Li, et al.
Journal of Medicinal Chemistry|January 30, 2007
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancerWenqing Yao, Jincong Zhuo, David M Burns, et al.
Pageof 7